Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy - Yamauchi, J; Coler-Reilly, A; Sato, T (J Infect Dis, 2015)
, et al.